Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morton Coleman

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2018
An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated MyelomaVincent L Hansen, Morton Coleman, Stephanie Elkins, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2013
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myelomaTomer M Mark, Whitney Reid, Ruben Niesvizky, et al.
Cancer|March 18, 2010
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphomaJia Ruan, Peter Martin, Morton Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphomaJia Ruan, Elizabeth Hyjek, Pouneh Kermani, et al.
Cancer|October 26, 2006
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu, Stanley J Goldsmith, John P Leonard, et al.
Leukemia Research|May 4, 2007
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphomaGail J Roboz, John M Bennett, Morton Coleman, et al.
Cancer|July 29, 2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphomaRichard R Furman, Peter Martin, Jia Ruan, et al.
American Journal of Clinical Pathology|March 21, 2012
Composite chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma are biclonal lymphomas: a report of two casesLeonardo Boiocchi, Rosanny Espinal Witter, Bing He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinibZibo Song, Pin Lu, Richard R Furman, et al.
Blood Advances|February 23, 2019
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myelomaTomer M Mark, Peter A Forsberg, Adriana C Rossi, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2018
An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated MyelomaVincent L Hansen, Morton Coleman, Stephanie Elkins, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2013
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myelomaTomer M Mark, Whitney Reid, Ruben Niesvizky, et al.
Cancer|March 18, 2010
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphomaJia Ruan, Peter Martin, Morton Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphomaJia Ruan, Elizabeth Hyjek, Pouneh Kermani, et al.
Cancer|October 26, 2006
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseLale Kostakoglu, Stanley J Goldsmith, John P Leonard, et al.
Leukemia Research|May 4, 2007
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphomaGail J Roboz, John M Bennett, Morton Coleman, et al.
Cancer|July 29, 2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphomaRichard R Furman, Peter Martin, Jia Ruan, et al.
American Journal of Clinical Pathology|March 21, 2012
Composite chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma are biclonal lymphomas: a report of two casesLeonardo Boiocchi, Rosanny Espinal Witter, Bing He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinibZibo Song, Pin Lu, Richard R Furman, et al.
Blood Advances|February 23, 2019
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myelomaTomer M Mark, Peter A Forsberg, Adriana C Rossi, et al.
Pageof 12